JAOA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


JAOA • Vol 105 • No 4_suppl • April 2005 • 9-15
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nissan, G. R.
Right arrow Articles by Diamond, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nissan, G. R.
Right arrow Articles by Diamond, M. L.

Advances in Migraine Treatment

George R. Nissan, DO; Merle L. Diamond, MD

Dr Nissan is a staff physician at the Diamond Headache Clinic, and Dr Diamond is associate director of the Diamond Headache Clinic in Chicago, Ill. Dr Diamond is also a clinical assistant professor in the Department of Medicine at The Chicago Medical School at Rosalind Franklin University of Medicine and Science, in North Chicago, Ill.

Address correspondence to George R. Nissan, DO, Diamond Headache Clinic, 467 W Deming Pl, Suite 500, Chicago, IL 60614-2970.E-mail: gnissan{at}diamondheadache.com

Migraine is a common, incapacitating disorder that is underdiagnosed in clinical practice. Early and correct diagnosis of migraine is essential and can lead to significant improvements in a patient's quality of life. In the clinical practice setting, a screening tool can be used that can help differentiate migraine from other headache disorders. New research into the development of central sensitization and cutaneous allodynia in chronic migraine sufferers has led to an early treatment approach with triptans and other agents for acute migraine episodes. This approach results in greater 2-hour headache pain-free results. The use of botulinum toxin type A in the prophylaxis of migraine and mixed-headache types offers an alternative treatment in patients who may not have responded to other currently available migraine prophylactic agents.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Osteopathic Association.